KOLINPHARMA
I prodotti Kolinpharma
News
From Kolinpharma world
06/12/2022
KOLINPHARMA®: has achieved the first patent for Xinprox®

KOLINPHARMA® S.p.A. is proud to communicate the first patent for XINPROX®.

XINPROX®, studied and developed for the well – being of the prostate, it is a food supplement which includes in the formulation raw materials of high quality, technologically advanced and supported by scientific studies, such as pollen extract, quercetin, alpha lipoic acid and L-tryptophan.

Now, Kolinpharma has 46 patents in total, 7 in Italy, 6 in USA, 1 in Israel and 32 in the principal States of UE. Rita Paola Petrelli, president of Kolinpharma has commented: “We are proud to announce that we have achieved the first patent for Xinprox® which testifies the validity of the formulations and the work of the R&D department and of the all company. […] The research is one of our elements of strengths and for this reason, we want to continue and invest and value our product to offer to costumer – patient scientifically validated solutions, patent is synonymous of synergy, uniqueness and innovation".


< Back
Ultime news
KOLINPHARMA® INCLUDED AMONG THE 100 ITALIAN EXCELLENCES
20/12/2024
KOLINPHARMA® INCLUDED AMONG THE 100 ITALIAN EXCELLENCES
KOLINPHARMA® has obtained the recognition of "Growth Leader 2025" for the sixth consecutive year
23/12/2024
KOLINPHARMA® has obtained the recognition of "Growth Leader 2025" for the sixth consecutive year
Metatag
Respect the environment, Company validations, Certified products, Homepage, Nutraceuticals , Profile and organization, Research and development, Consumer Protection
“Science accuracy and listen to people”
“Science accuracy and listen to people”